This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-36 (canceled).

Claim 37 (new): A pharmaceutical formulation comprising crystalline and/or amorphous unmilled flutamide particles mixed with at least one surface-active substance, wherein the flutamide has been subjected to intensive mixing in a forced-action mixture with the at least one surface-active substance.

Claim 38 (new): The pharmaceutical formulation of claim 37, wherein said formulation further comprises at least one flow regulator and is in the form of a tablet.

Claim 39 (new): The pharmaceutical formulation of claim 37, wherein said formulation is in the form of a filling for capsules.

Claim 40 (new): The pharmaceutical formulation of claim 37, wherein said formulation is in the form of a dragée, effervescent tablet, suppository or granulate.

Claim 41 (new): The pharmaceutical formulation of claim 37, wherein the flutamide has been subjected to recrystallisation.

Claim 42 (new): The pharmaceutical formulation of claim 37, wherein the flutamide particles comprise a mean particle size greater than the mean particle size of flutamide that, with an initial particle size of from 5 to 240 μm, has been subjected to a milling operation.

Claim 43 (new): The pharmaceutical formulation of claim 37, wherein the size of 50% of the flutamide particles (X50 value) is greater than 20 μm.

Claim 44 (new): The pharmaceutical formulation of claim 43, wherein the size of 50% of the flutamide particles (X50 value) is greater than 26 μm.

Claim 45 (new): The pharmaceutical formulation of claim 37, wherein the size of 90% of the flutamide particles (X90 value) is greater than 60 μm.

Claim 46 (new): The pharmaceutical formulation of claim 45, wherein the size of 90% of the flutamide particles (X90 value) is greater than 130 μm.

Claim 47 (new): The pharmaceutical formulation of claim 37, wherein the flutamide particles have a specific surface area of less than 2.50 m^2/cm^3.

Claim 48 (new): The pharmaceutical formulation of claim 47, wherein the flutamide particles have a specific surface area of less than 1.50 m^2/cm^3.

Claim 49 (new): The pharmaceutical formulation of claim 48, wherein the flutamide particles have a specific surface area of less than 0.35 m^2/cm^3.

Claim 50 (new): The pharmaceutical formulation of claim 37, wherein the flutamide is in the form of a free acid amide or a pharmaceutically acceptable solvate.

Claim 51 (new): The pharmaceutical formulation of claim 37, wherein the at least one surface-active substance is selected from the group of an anionic compound, cationic compound and non-ionic surfactant.

Claim 52 (new): The pharmaceutical formulation of claim 51 comprising sodium dodecylsulphate as surface-active substance.

Claim 53 (new): The pharmaceutical formulation of claim 37 with a ratio by weight of flutamide:surface-active substance of from 5:1 to 30:1.

Claim 54 (new): The pharmaceutical formulation of claim 53 with a ratio by weight of flutamide:surface-active substance of from 5:1 to 20:1.

Claim 55 (new): The pharmaceutical formulation of claim 54 with a ratio by weight of flutamide:surface-active substance of from 10:1 to 15:1.

Claim 56 (new): The pharmaceutical formulation of claim 37 in the form of an unshaped mixture or in the form of an article that has been subjected to shaping.

Claim 57 (new): The pharmaceutical formulation of claim 56 with a content of from 50 to 2000 mg of flutamide.

Claim 58 (new): The pharmaceutical formulation of claim 57 with a content of from 50 to 500 mg of flutamide.

Claim 59 (new): The pharmaceutical formulation of claim 58 with a content of from 100 to 200 mg of flutamide.

Claim 60 (new): The pharmaceutical formulation of claim 37, further comprising at least one excipient selected from the group formed by inorganic fillers, organic fillers, binders, glidants, lubricants, flow regulators and disintegrants.

Claim 61 (new): The pharmaceutical formulation of claim 37, wherein the formulation is mixed in a forced-action mixture for 1 to 180 minutes.

Claim 62 (new): The pharmaceutical formulation of claim 61, wherein the formulation is mixed in a forced-action mixture for 3 to 60 minutes.